Executed comprehensive in vitro cytotoxicity and dose-response experiments, supporting robust hazard identification and contributing to the preclinical evaluation of novel compounds.
Pioneered biomarker discovery and validation through epigenetic analyses and molecular diagnostic assay development (ChIP, qRT-PCR, dual luciferase), directly contributing to 4 co-authored publications in high-impact journals (Mol Cell, JBC).
Characterized stress-induced protein and RNA expression changes using Western blotting, Northern blotting, and SDS-PAGE, enabling quantitative analysis of pathway activation and ensuring sample quality for downstream applications.
Engineered custom plasmids for gene expression studies via molecular cloning (SNAPGene, Addgene) and validated subcellular localization and protein interactions using immunofluorescence microscopy and flow cytometry.
Processed and analyzed complex experimental data, quantifying gel images with Image Quant and performing statistical analysis in GraphPad Prism, resulting in publication-ready figures and presentations for scientific dissemination.
Contributed to 4 high-impact publications (Molecular Cell, JBC) by executing multi-channel research campaigns and translating complex data into actionable scientific insights, mirroring market strategy development.
Managed end-to-end laboratory operations for NIH-funded projects, including inventory control, vendor negotiations, and scheduling, reducing annual operational costs by $65K (20%) through strategic vendor management and supply chain optimization.
Ensured audit-ready, GLP-compliant documentation, managed equipment/supply inventories, and oversaw sample logistics, maintaining regulatory adherence and operational efficiency.